Copyright
©The Author(s) 2022.
World J Clin Cases. Dec 26, 2022; 10(36): 13189-13199
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13189
Published online Dec 26, 2022. doi: 10.12998/wjcc.v10.i36.13189
Table 1 Use of probiotics in the prevention of gestational diabetes and infant outcomes in overweight and obese pregnant women
Ref. | Participant | Strain | Dosage | Administration method | Administration duration | Sample size | Results |
Lindsay et al[55], 2014 | BMI 30.0-39.9 kg/m2 | Lactobacillus salivarius UCC118 | 109 CFU/d | Probiotic or placebo capsules refrigerated after a meal | 24-28 wk gestation | 175 (IG: 63; CG: 75) | FPG (probiotic: 4.60 mmol/L; placebo: 4.69 mmol/L, P = 0.391). Insulin (probiotic: 15.63 mU/L; placebo: 16.88 mU/L, P =0.16). HOMA2-IR (probiotic: 3.26; placebo: 3.53, P = 0.16). C-peptide (probiotic: 3.32 ng/mL; placebo: 3.37 ng/mL, P = 0.184). Total cholesterol (probiotic: 6.33 mmol/L; placebo: 6.60 mmol/L, P = 0.571). Total GWG (probiotic: 11.1 ± 6.2 kg vs placebo: 9.4 ± 5.6 kg, P = 0.479). PE (probiotic: 4.8%; placebo: 2.7%, P = 0.09) |
Asgharian et al[6], 2020 | Pre- or early-pregnancy BMI ≥ 25 kg/m2 | Lactobacillus acidophilus La5 and Bifidobacterium lactis Bb12 | 100 g/d (5 × 108 CFU/g) | Probiotic or conventional yoghurt refrigerated | 24 wk of gestation until delivery | 130 (IG: 64; CG: 64) | FPG (probiotic yoghurt: 74.8 mg/dL; conventional yoghurt: 77.9 mg/dL, P = 0.008). 1 h OGTT (probiotic yoghurt: 128.0 mg/dL; conventional yoghurt: 136.0 mg/dL, P = 0.071). 2 h OGTT (probiotic yoghurt: 103.9 mg/dL; conventional yoghurt: 115.5 mg/dL, P = 0.002). GDM (probiotic yoghurt: 9%; conventional yoghurt: 17%, P = 0.184). Preeclampsia (probiotic yoghurt: 2%; conventional yoghurt: 0, P = 0.997). Preterm birth (probiotic yoghurt: 5%; conventional yoghurt: 13%, P = 0.077). Cesarean delivery (probiotic yoghurt: 52%; conventional yoghurt: 35%, P = 0.695). Total bilirubin on days 3-5 after birth (probiotic yoghurt: 9.1 mg/dL; conventional yoghurt: 11.3 mg/dL, P < 0.001). Treatment for hyperbilirubinemia (probiotic yoghurt: 36%; conventional yoghurt: 59%, P = 0.001). Phototherapy for hyperbilirubinemia (probiotic yoghurt: 16%; conventional yoghurt: 42%, P = 0.001) |
Callaway et al[51], 2019 | BMI > 25 kg/m2 | Lactobacillus rhamnosus (LGG) and Bifidobacterium animalis subsp. lactis(BB-12) | 109 CFU/d | Probiotic or placebo capsules | Recruitment (12-20 wk of gestation) until birth | 433 (IG: 207; CG: 204) | GDM (probiotic: 18.4%; placebo: 12.3%, P = 0.184). FPG (probiotic: 79.3 mg/dL; placebo: 77.5 mg/dL, P = 0.049). PE (probiotic: 9.2%; placebo: 4.9%, P = 0.09). 28 wk diastolic BP (probiotic: 66.4 mmHg; placebo: 65 mmHg, P = 0.070). Excess weight gain (probiotic: 32.5%; placebo: 46%, P = 0.01). SAG < 10th percentile (probiotic: 2.4%; placebo: 6.5%, P = 0.042) |
Pellonperä et al[3], 2019 | BMI ≥ 25 kg/m2 | Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis 420 | 1010 CFU/d | Probiotic or placebo capsules refrigerated | 13.9 ± 2.1 wk of gestation until 6 mo postpartum | 439 (fish oil + placebo: 109; probiotics + placebo: 110; fish oil + probiotics: 109; placebo + placebo: 110) | -GDM (fish oil + placebo: 32.5%; probiotics + placebo: 28.4%; fish oil + probiotics: 36.9%; placebo + placebo: 36.9%, P = 0.59). Insulin (fish oil + placebo: 8.0 mU/L; probiotics + placebo: 5.5 mU/L; fish oil + probiotics: 6.6 mU/L; placebo + placebo: 6.4 mU/L, P = 0.16). HOMA2-IR (fish oil + placebo: 0.98; probiotics + placebo: 0.65; fish oil + probiotics: 0.80; placebo + placebo: 0.75, P = 0.12). SAG < 10th percentile (fish oil + placebo: 7.6%; probiotics + placebo: 7.3%; fish oil + probiotics: 8.7%; placebo + placebo: 9.8%, P = 0.93) |
Okesene-Gafa et al[4], 2020 | BMI ≥ 30 kg/m2 | Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12 | 6.5 × 109 CFU | Probiotic or placebo capsules | Recruitment (12-17 wk) until birth | 230 (IG: 115; CG: 115) | Excess weight gain (probiotic: 82.4%; conventional: 73.4%, P = 0.08). GDM (probiotic: 26.7% vs placebo: 27.5%, P = 0.80). Birthweight (probiotic: 3684 g vs placebo: 3504 g, P = 0.08) |
Halkjær et al[41], 2020 | BMI ≥ 30 and < 35 kg/m2 | Probiotic mixture Vivomixx® (Streptococcus thermophilus DSM 24731, bifidobacteria and lactobacilli) | 450 × 109 CFU/d | Probiotic or placebo capsules refrigerated | 14-20 wk of gestation until delivery | 50 (IG: 25; CG: 24) | Total GWG (probiotic: 12.7 ± 5.3 kg vs placebo: 13.1 ± 5.8 kg, P = 0.82). Intervention period weight gain (probiotic: 10.2 ± 3.4 vs placebo: 10.0 ± 4.2, P = 0.87). Birthweight (probiotic: 3608 g vs placebo: 3640 g, P = 0.82). GDM (probiotic: 16% vs placebo: 8%, P = 0.67) |
Shahriar et al[7], 2021 | High-risk pregnant women for GDM including BMI > 25 kg/m2 | Mixture of Lactobacillus acidophilus LA1, Bifidobacterium longum sp54 cs, and Bifidobacterium bifidum sp9 cs | 500 mg/d, 9.6 × 109 CFU | Probiotic or placebo capsules with a glass of water or milk (acidic or hot drinks were avoided) | 14 wk of pregnancy up to 24 wk | 542 (IG: 241; CG: 266) | GDM (probiotic: 41.9% vs placebo: 40.2%, P = 0.780). PE (probiotic: 17.8%; placebo: 17.3%, P = 0.87) |
- Citation: Deng YF, Wu LP, Liu YP. Probiotics for preventing gestational diabetes in overweight or obese pregnant women: A review. World J Clin Cases 2022; 10(36): 13189-13199
- URL: https://www.wjgnet.com/2307-8960/full/v10/i36/13189.htm
- DOI: https://dx.doi.org/10.12998/wjcc.v10.i36.13189